These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 10973322)

  • 1. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.
    Molldrem JJ; Lee PP; Wang C; Felio K; Kantarjian HM; Champlin RE; Davis MM
    Nat Med; 2000 Sep; 6(9):1018-23. PubMed ID: 10973322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
    Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.
    Molldrem JJ; Lee PP; Wang C; Champlin RE; Davis MM
    Cancer Res; 1999 Jun; 59(11):2675-81. PubMed ID: 10363991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.
    Molldrem JJ; Lee PP; Kant S; Wieder E; Jiang W; Lu S; Wang C; Davis MM
    J Clin Invest; 2003 Mar; 111(5):639-47. PubMed ID: 12618518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
    Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.
    Molldrem JJ; Clave E; Jiang YZ; Mavroudis D; Raptis A; Hensel N; Agarwala V; Barrett AJ
    Blood; 1997 Oct; 90(7):2529-34. PubMed ID: 9326217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular cytokine analysis of interferon-gamma in T cells of patients with chronic myeloid leukemia.
    Aswald JM; Lipton JH; Messner HA
    Cytokines Cell Mol Ther; 2002 Dec; 7(2):75-82. PubMed ID: 12607798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation.
    Chen J; Schmitt A; Bunjes D; Chen B; Schmitt M
    Int J Oncol; 2007 May; 30(5):1119-27. PubMed ID: 17390013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
    Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator-responder pairs.
    Fujiwara H; Sconocchia G; Melenhorst J; Eniafe R; Nakamura R; Hensel N; Barrett AJ
    Bone Marrow Transplant; 2003 Aug; 32(4):371-8. PubMed ID: 12900773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
    Burchert A; Wölfl S; Schmidt M; Brendel C; Denecke B; Cai D; Odyvanova L; Lahaye T; Müller MC; Berg T; Gschaidmeier H; Wittig B; Hehlmann R; Hochhaus A; Neubauer A
    Blood; 2003 Jan; 101(1):259-64. PubMed ID: 12393722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population.
    Maury S; Belhadj K; Chami I; Kuentz M; Cordonnier C; Bories D
    Bone Marrow Transplant; 2001 Oct; 28(7):717-20. PubMed ID: 11704798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.
    Li Z; Qiao Y; Liu B; Laska EJ; Chakravarthi P; Kulko JM; Bona RD; Fang M; Hegde U; Moyo V; Tannenbaum SH; Ménoret A; Gaffney J; Glynn L; Runowicz CD; Srivastava PK
    Clin Cancer Res; 2005 Jun; 11(12):4460-8. PubMed ID: 15958631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay.
    Smit WM; Rijnbeek M; van Bergen CA; Willemze R; Falkenburg JH
    Bone Marrow Transplant; 1998 Mar; 21(6):553-60. PubMed ID: 9543058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers.
    Beksac M; Celebi H; Sargín D; Yalcin A; Topcuoglu P; Kalayoglu-Besisik S; Beyan C; Arslan O; Ozcan M; Gurman G; Ilhan O; Akan H
    Bone Marrow Transplant; 2003 May; 31(10):897-904. PubMed ID: 12748666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion and activation of minor histocompatibility antigen HY-specific T cells associated with graft-versus-leukemia response.
    Takami A; Sugimori C; Feng X; Yachie A; Kondo Y; Nishimura R; Kuzushima K; Kotani T; Asakura H; Shiobara S; Nakao S
    Bone Marrow Transplant; 2004 Oct; 34(8):703-9. PubMed ID: 15322566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.